{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-20168286-lanreotide:v1","objectPathId":"pubmed-pmid-20168286-lanreotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-20168286-lanreotide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-20168286-lanreotide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-20168286-lanreotide-v1.md"},"story":{"slug":"pubmed-pmid-20168286-lanreotide","version":1,"domain":"Literature metadata","dateInSource":"2016-11-25","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["lanreotide"],"peptides":[{"slug":"lanreotide","url":"https://peptidescanner.com/peptides/lanreotide/"}]},"claims":[{"id":"headline","text":"Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.","sourceIds":["pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869"]},{"id":"summary","text":"PubMed lists PMID 20168286 in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... as Clinical Trial, Journal Article, with publication-date metadata of 2010-02 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869"]},{"id":"paragraph-1","text":"PubMed lists PMID 20168286 in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... as Clinical Trial, Journal Article, with publication-date metadata of 2010-02 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869"]}],"sources":[{"id":"pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869","name":"PubMed","sourceClass":"A","title":"Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. · retained source version 1:2016-11-25:current:d1ab9efa1869c48145852bbef1f2dde7fa559213e4a6dcbd278c26e3c2197c94","url":"https://pubmed.ncbi.nlm.nih.gov/20168286/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"cfcb2c3cf75ae7a3bf5fb21f3334b8cc7a90d61fb96fc80ac782ee45f9cb6d81","tierARecordSha256":"a9b76f06a41292e61631ecdaed1e4b198d67164068686f46e27b29697987593b"},"integrity":{"algorithm":"sha256","contentSha256":"3aab52d668f9ec05bda8924d548f1e1778da7a43056768d4b95b339fec6c7880"}}